P-156 - UPDATED PHYSIOLOGICAL BASED PHARMACOKINETIC MODELLING OF OSIMERTINIB FOR ASSESSMENT OF DRUG-DRUG INTERACTION WITH CYP1A2 AND CYP2C8 SUBSTRATES.
P. Sharma1, M. Wild1, M. Johnson2, K. Vishwanathan3; 1AstraZeneca, Cambridgeshire, United Kingdom, 2AstraZeneca, Cambridge, United Kingdom, 3AstraZeneca, Waltham, MA, USA.